The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 13 April 2026•Updated 13 April 2026•

1 min read

Global Markets: Sun Pharma Bids $12B for Organon Amid Strong Corporate Earnings and AI Deals

Key Facts

1Sun Pharmaceutical Industries is advancing a $12 billion binding offer to acquire Organon (OGN).

about 2 months ago

Version History

2 additional sources confirmed this story

Version 1about 2 months ago

What changed: Added ResMed (RMD) stock analysis, including Evercore ISI price target, insider selling details, and the upcoming earnings date.

Global corporate activity surged as Sun Pharmaceutical Industries advanced a $12 billion binding offer to acquire Organon (OGN), marking a significant consolidation in healthcare. In the technology space, Google deepened its strategic partnership with Intel to enhance AI infrastructure, while retail giant Fast Retailing reported record profits and raised its 2026 outlook. Adding to market analysis, Evercore ISI set a $255 price target for ResMed (RMD) ahead of its Q3 earnings report scheduled for April 30, 2026. However, recent filings indicated that ResMed insiders sold $1.5 million worth of shares, providing a cautionary data point for investors. Meanwhile, the mining sector saw G Mining Ventures acquire G2 Goldfields, and Simulations Plus (SLP) outperformed expectations with an 8% revenue increase. These developments reflect a robust trend of consolidation and growth, balanced by specific stock-level insider activity.